Slide 1: Strategic Transaction with Almirall in Respiratory Disease
Strategic vz Transaction with Almirall in Respiratory Disease Accelerating AstraZeneca Respiratory Leadership July 30, 2014 1
Slide 2: Long-term value generation and strong strategic fit
Long-term value generation and strong strategic fit 1 Stronger inhaled portfolio in asthma and COPD Greater device choice for patients (DPI and pMDI)1 Short-term: adds DPI twice daily LAMA & LABA/LAMA options to Symbicort/ Pearl Medium-term: offers once daily treatment options with novel MABA
Slide 3: Summary Transaction Overview
Summary Transaction Overview Aclidinium franchise: Eklira® (LAMA) and LAS40464 (LAMA/LABA) Development and commercial rights in un-partnered territories Assume Almirall rights in partnered territories Clinical assets and discovery collaboration Global development and commercial rights on MABA
Slide 4: Progressing AstraZeneca leadership in Respiratory
Progressing AstraZeneca leadership in Respiratory Revenue and access to Strengthen AstraZeneca Strengthen AstraZeneca in-market portfolio pipeline device offering and know-how Eklira® Genuair® QD MABA Device • Growing, marketed product • New class of bronchodilators • Current and future DPI platform
Slide 5: Significant long-term commercial potential
Significant long-term commercial potential $2bn+ peak sales potential (non-risk adjusted) COPD Bronchodilators1 Triple therapy2 >$1Bn >$1Bn Peak sales Peak sales 1 Includes forecast global sales from partners on Aclidinium monotherapy, combination LABA/LAMA therapy and MABA monotherapy in COPD 2 Inc
Slide 6: Accelerating our Respiratory Leadership
Accelerating our Respiratory Leadership 6
Slide 7: Better positioned to capture the triple therapy opportunity
Better positioned to capture the triple therapy opportunity Almirall MABA programme: Triple Therapy: profile and rationale commercial potential • Series of 3 MABA assets • Increasingly regarded as the “holy grail” of COPD therapy • Lead asset currently in P1 • Potential for c.30% of COPD patients wi
Slide 8: Improved DPI device offering and capabilities
Improved DPI device offering and capabilities Competitive positioning: Strong device strategy fit device choice and effective use are key > 57% of physicians believe device is Improves choice for patient & physician important of dry powder and active / pressurized metered dose inhalers DPI’s d
Slide 9: Strong performance from launch in Europe
Strong performance from launch in Europe 5.2% LAMA market share % Share of LAMA Market* (DoT) : Europe % share 7.0 6.0 5.9 5.2 5.0 4.0 3.0 2.0 1.0 0.0 SEEBRI TOTAL Eklira + Bretaris * tiotropium, glycopyrronium, aclidinium 9 Source: IMS (combined) * Tiotropium, Glycopyrronium, Aclidinium